Generation of a CRISPR/Cas9-corrected isogenic control iPSC line (NIMHi001-A-1) from a Parkinson's disease Patient-Derived iPSC line carrying the LRRK2 I1371V mutation.
The NIMHi001-A-1 line demonstrated trilineage differentiation potential and tested negative for mycoplasma, providing an isogenic platform to investigate LRRK2 I1371V-specific pathomechanisms and evaluate therapeutic strategies.